Welcome to our dedicated page for Dr Reddys Labs SEC filings (Ticker: RDY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Dr. Reddy's Laboratories Limited (RDY) SEC filings page on Stock Titan brings together the company’s U.S. regulatory disclosures as a foreign private issuer listed on the New York Stock Exchange. Dr. Reddy's files reports such as Form 6-K with the Securities and Exchange Commission, providing investors with access to financial results, board and corporate actions, and other information furnished under its home-country requirements.
Key filing types for Dr. Reddy's include periodic Form 6-K submissions that often attach consolidated IFRS financial statements, segment data for Global Generics and Pharmaceutical Services and Active Ingredients (PSAI), and management commentary on revenue trends, R&D spending and regional performance. These filings can also include intimations regarding board meetings, corporate actions and other material updates first disclosed in India.
For a pharmaceutical manufacturer active in APIs, generics, branded generics, biosimilars and OTC products, SEC filings are a primary source for understanding segment performance, geographic mix and investment in R&D. Investors can use them to track how Dr. Reddy's generics and biosimilars portfolios evolve, how collaborations and acquisitions contribute to results, and how the company allocates capital across regions and product categories.
On Stock Titan, each new RDY filing from EDGAR is captured and organized chronologically. AI-powered summaries help explain the main points of lengthy documents, highlighting items such as revenue movements, margin changes, R&D focus areas and notable regulatory or ESG disclosures. Users can quickly scan these summaries before diving into the full text of a 6-K or related exhibits.
In addition to financial information, this page can surface filings that relate to governance, risk and compliance, complementing press releases about inspections, recalls or ESG recognitions. Together, these documents provide a structured view of Dr. Reddy's regulatory footprint in the U.S. and support deeper analysis of the RDY stock for research-oriented investors.
DR REDDYS LABORATORIES LTD executive Patrick Rudolf Aghanian, Head - Europe Generics, filed an initial insider ownership report. The filing shows direct beneficial ownership of 8,450 Equity Shares underlying ADRs, with no reported purchases or sales associated with this filing.
DR REDDYS LABORATORIES LTD executive Milan Kantilal Kalawadia, CEO – North America, has filed an initial Form 3 reporting his ownership in the company. The filing lists 47,325 Equity Shares underlying ADRs held with direct ownership, and does not report any recent purchases or sales.
DR REDDYS LABORATORIES LTD executive Motupalli Venkata Ramana, who serves as CEO - Global Generics, has filed an initial ownership report showing direct holdings of 68,230 Equity Shares of the company. This Form 3 reflects his beneficial ownership position rather than a new buy or sell transaction.
DR REDDYS LABORATORIES LTD filed an initial insider ownership report for Israeli Erez, who is listed as the company’s CHIEF EXECUTIVE OFFICER. This Form 3 shows no reported purchases, sales, or other transactions in the company’s securities and provides only role and status information.
Dr. Reddy's Laboratories Ltd officer Venkatesh Krishna, Global Head - IPDO, has filed an initial Form 3 as a reporting person. The filing in this excerpt lists no equity transactions or derivative positions, and serves mainly to establish his status as an insider subject to SEC reporting rules.
DR REDDYS LABORATORIES LTD executive Sushrut Kulkarni, Global Head - IPDO, filed an initial ownership report showing beneficial ownership of 70 Equity Shares of the company. These shares are reported as held under direct ownership, with no buy or sell transaction disclosed in this filing.
DR REDDYS LABORATORIES LTD reported the initial holdings of Chief Information Officer Bhethanabottla Srinivasa Phanimitra on a Form 3. The filing shows direct ownership of 8,712 Equity Shares after the reported entry. This is a disclosure of existing beneficial ownership rather than a new stock purchase or sale.
DR REDDYS LABORATORIES LTD Chief Financial Officer Mannam Venkata Narasimham filed an initial ownership report showing his stake in the company. The Form 3 lists direct ownership of 61,245 Equity Shares, providing a baseline of his holdings as an executive but does not report any recent share purchases or sales.
DR REDDYS LABORATORIES LTD executive Deepak Sapra has filed an initial Form 3 reporting his equity holdings. As CEO - API and Services, he reports beneficial ownership of 75,624 equity shares held directly. This filing lists his position as of the reporting date and does not show any recent buy or sell transaction.
DR REDDYS LABORATORIES LTD director Alpna Seth filed an initial Form 3, which identifies her as a reporting person for the company. The filing shows no reported transactions or derivative positions and serves as a baseline disclosure of her status under insider reporting rules.